^
Association details:
| Biomarker: | BAP1 mutation |
|---|---|
| Cancer: | Renal Cell Carcinoma |
| Drug Class: | Tyrosine kinase inhibitor |
| Direction: | Resistant |
Evidence:
Source:
Title:
Genomic alterations in metastatic renal cell carcinoma (mRCC): Impact on survival and clinical outcomes.
Published date:
02/13/2023
Excerpt:
CONTRADICTING EVIDENCE: 2-yr OS for pts with a VHL mutation was 93% (95% CI: 82-97) vs. 68% (95%CI: 54-78) for pts without (p=0.01)... For pts with SETD2 mutations treated with IO/IO, mPFS was 0.7yrs (95%CI 0.3-1.2) vs. 1.4yrs (95%CI 0.8-1.9) for IO/TKI (p=0.01). For pts with BAP1 mutations treated with IO/IO, mPFS was 0.4yrs (95%CI 0.2-1.2) vs. NE (95%CI 0.2-NE) for IO/TKI (p=0.04)...VHL mutation was associated with improved 2-yr OS. Pts with SETD2 and BAP1 mutations treated with IO/TKI had improved mPFS...
DOI:
https://meetings.asco.org/abstracts-presentations/216557
Source:
Title:
Alterations in key clear cell renal cell carcinoma (RCC) genes to refine patient prognosis.
Published date:
05/16/2018
Excerpt:
...mRCC treated with 1st line VEGF tyrosine kinase inhibitor and tumor genomics available were included….Patients with tumors PBRM1 wild type and harboring GA in BAP1 had worse OS [37 vs 50 mos, aHR 1.9 (95%CI 1.2-2.8 p = 0.004].
DOI:
10.1200/JCO.2018.36.15_suppl.4516
